Profile of ocriplasmin and its potential in the treatment of vitreomacular adhesion

The recent approval by the US Food and Drug Administration of ocriplasmin for the treatment of symptomatic vitreomacular adhesion (VMA), often associated with vitreomacular traction (VMT) and macular hole (MH), has brought new attention to the field of pharmacologic vitreolysis. The need for an enzy...

Descripción completa

Detalles Bibliográficos
Autores principales: Stefanini, Francisco R, Maia, Maurício, Falabella, Paulo, Pfister, Marcel, Niemeyer, Moritz, Kashani, Amir H, Humayun, Mark S, Koss, Michael J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2014
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4018320/
https://www.ncbi.nlm.nih.gov/pubmed/24851038
http://dx.doi.org/10.2147/OPTH.S32274

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4018320/
https://www.ncbi.nlm.nih.gov/pubmed/24851038
http://dx.doi.org/10.2147/OPTH.S32274

Ejemplares similares